Honda, Natsuki
Ochi, Akinobu http://orcid.org/0000-0001-6809-8399
Uchimoto, Sadahiko
Kakutani, Yoshinori
Yamazaki, Yuko
Morioka, Tomoaki
Shoji, Tetsuo
Inaba, Masaaki
Emoto, Masanori
Article History
Received: 20 July 2021
Accepted: 9 December 2021
First Online: 24 January 2022
Declarations
:
: Natsuki Honda, Akinobu Ochi, Sadahiko Uchimoto, Yoshinori Kakutani, Yuko Yamazaki, Tomoaki Morioka, Masaaki Inaba and Masanori Emoto declare no conflicts of interests associated with this study. Tetsuo Shoji received an honorarium from Chugai Pharmaceutical Co., Ltd. (Tokyo, Japan) and Ono Pharmaceutical Co., Ltd. (Osaka, Japan), and received research funding from Ono Pharmaceutical Co. Ltd. and Bayer Yakuhin, Ltd. (Osaka City, Japan).
: All procedures were followed in accordance with the ethical standards of the responsible committee on human experimentation (the ethics committee of Fujiidera Municipal Hospital) and with the Helsinki Declaration of 1964 and later versions. T2D patients with AF have a higher risk of stroke. In the present study, we started anticoagulant therapy in AF patients who had not received anticoagulant therapy to prevent stroke, except for the patients with high risk of bleeding.